Literature DB >> 19368792

Extended safety studies of the attenuated live tuberculosis vaccine SO2 based on phoP mutant.

P J Cardona1, J Gonzalo Asensio, A Arbués, I Otal, C Lafoz, O Gil, N Caceres, V Ausina, B Gicquel, C Martin.   

Abstract

Safety is one of the main concerns for attenuated live vaccine candidates. Here we extend the stability and attenuation studies of the promising tuberculosis vaccine candidate based on Mycobacterium tuberculosis phoP mutant strain, SO2. Stability of the phoP mutation was tested after sub-culturing SO2 strain for 6 months in laboratory media and also after 3 months of infection in SCID mice. Results showed no reversion of the phoP mutation either in vitro or in vivo. In addition, SO2 was fully sensitive to four major first-line antituberculous drugs against tuberculosis. Safety and toxicity studies were performed in guinea pigs. Animals were infected with a quantity of SO2 equivalent to 50 vaccination doses (2.5x10(6) CFUs) and weight was monitored for 6 months. All animals survived and no histological lesions were found, showing full attenuation of SO2. Studies in a post-exposure model of guinea pigs and mice, previously infected with M. tuberculosis, were performed and no toxicity effects were found after inoculation of SO2. All these results together confirm that SO2 has a secure safety profile that encourages its use in clinical trials.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19368792     DOI: 10.1016/j.vaccine.2009.02.060

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

1.  Vaccination of guinea pigs using mce operon mutants of Mycobacterium tuberculosis.

Authors:  Andrés Obregón-Henao; Crystal Shanley; María Verónica Bianco; Angel A Cataldi; Randall J Basaraba; Ian M Orme; Fabiana Bigi
Journal:  Vaccine       Date:  2011-04-22       Impact factor: 3.641

Review 2.  Development of new vaccines and drugs for TB: limitations and potential strategic errors.

Authors:  Ian M Orme
Journal:  Future Microbiol       Date:  2011-02       Impact factor: 3.165

Review 3.  Tuberculosis vaccines in clinical trials.

Authors:  Rosalind Rowland; Helen McShane
Journal:  Expert Rev Vaccines       Date:  2011-05       Impact factor: 5.217

Review 4.  Tuberculosis vaccine types and timings.

Authors:  Ian M Orme
Journal:  Clin Vaccine Immunol       Date:  2014-12-24

5.  Humane Endpoints for Guinea Pigs Used for Mycobacterium tuberculosis Vaccine Research.

Authors:  Chereen Collymore; Laura Kent; Sang Kyun Ahn; Wenxi Xu; Ming Li; Jun Liu; Patricia V Turner; E Kate Banks
Journal:  Comp Med       Date:  2018-02-01       Impact factor: 0.982

6.  An aqueous extract of Yunnan Baiyao inhibits the quorum-sensing-related virulence of Pseudomonas aeruginosa.

Authors:  Zu-Guo Zhao; Shuang-Shuang Yan; Yun-Mei Yu; Na Mi; La-Xi Zhang; Jun Liu; Xiao-Ling Li; Fang Liu; Jun-Fa Xu; Wei-Qing Yang; Guo-Ming Li
Journal:  J Microbiol       Date:  2013-04-27       Impact factor: 3.422

Review 7.  Adaptation to environmental stimuli within the host: two-component signal transduction systems of Mycobacterium tuberculosis.

Authors:  Daniel J Bretl; Chrystalla Demetriadou; Thomas C Zahrt
Journal:  Microbiol Mol Biol Rev       Date:  2011-12       Impact factor: 11.056

8.  Extended safety and efficacy studies of a live attenuated double leucine and pantothenate auxotroph of Mycobacterium tuberculosis as a vaccine candidate.

Authors:  Samantha L Sampson; Keith G Mansfield; Angela Carville; D Mitchell Magee; Teresa Quitugua; Elizabeth W Howerth; Barry R Bloom; Mary K Hondalus
Journal:  Vaccine       Date:  2011-05-05       Impact factor: 3.641

9.  Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell death.

Authors:  Adriana Aporta; Ainhoa Arbues; Juan I Aguilo; Marta Monzon; Juan J Badiola; Alba de Martino; Nadia Ferrer; Dessislava Marinova; Alberto Anel; Carlos Martin; Julian Pardo
Journal:  PLoS One       Date:  2012-09-19       Impact factor: 3.240

10.  Intracellular Cytokine Staining and Flow Cytometry: Considerations for Application in Clinical Trials of Novel Tuberculosis Vaccines.

Authors:  Steven G Smith; Kaatje Smits; Simone A Joosten; Krista E van Meijgaarden; Iman Satti; Helen A Fletcher; Nadia Caccamo; Francesco Dieli; Francoise Mascart; Helen McShane; Hazel M Dockrell; Tom H M Ottenhoff
Journal:  PLoS One       Date:  2015-09-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.